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Intravenous methoxy polyethylene 
glycol-epoetin-β to control 
hemoglobin in CKD patients on 
dialysis
Using conventional epoetin to treat anemia in chronic kidney 
disease (CKD) requires frequent administrations, changes of 
dose, and close monitoring of hemoglobin concentrations. In a 
new study published in The Lancet, Levin et al.1 compared the 
eﬀectiveness of a newer epoetin, methoxy polyethylene glycol-
epoetin-β, with conventional epoetin treatment for hemoglobin 
control in hemodialysis patients. In the open-label, parallel-group, 
non-inferiority trial, the authors established baseline hemoglobin 
concentration and eligibility for 4 weeks. Patients were randomly 
assigned to receive methoxy polyethylene glycol-epoetin-β every 
2 weeks or every 4 weeks, or standard epoetin treatment given 
one to three times per week. The primary end point was change 
in hemoglobin concentration between baseline and the assess-
ment period. The mean change from baseline hemoglobin for 
patients who had switched to intravenous methoxy polyethylene 
glycol-epoetin-β every 2 weeks (–0.71 g per liter, 95% conﬁdence 
interval –2.20 to 0.77) or every 4 weeks (–0.25 g per liter, –1.79 
to 1.29) was comparable to the mean change for patients who 
continued treatment with epoetin (–0.75 g per liter, –2.26 to 
0.75) (P < 0.0001 for both comparisons). Among the patients 
who received at least one dose of study drug, the incidence of 
adverse events or serious adverse events did not diﬀer between 
groups (P = 0.30 and P = 0.40, respectively). The authors con-
clude that this long-acting erythropoiesis-stimulating agent is as 
safe as conventional epoetin treatment and can maintain anemia 
management in hemodialysis patients when given intravenously 
at 4-week dosing intervals.
In an accompanying commentary, Walker and Strippoli2 state 
that the study results may have limited strength and uncertain 
clinical relevance. The authors’ suggestion that traditional epoet-
ins’ short half-lives require frequent administration to maintain 
hemoglobin might be too simplistic; characteristics such as chemi-
cal structure and binding aﬃnity for the receptor might also have 
a role. The authors explain that diﬀerent studies have produced 
diﬀerent outcomes in terms of the degree of stability of hemo-
globin with these agents. Walker and Strippoli agree that the study 
makes a contribution to our understanding of the complexities of 
managing anemia in CKD. But they stipulate that before we can 
concur on a precise clinical role for this new molecule, we need 
to explore issues other than the comparability with other epoet-
ins to reach certain unvalidated surrogates. Diﬀerent doses and 
molecular characteristics of epoetins may aﬀect patient-level end 
points independent of achieved hemoglobin. When these issues 
are examined, we may be more conﬁdent that the newer molecule 
is comparable to existing ones. (1Lancet 2007; 370: 1415–1421. 
2Lancet 2007; 370: 1395–1396)
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TLR4 enhances TGF-β signaling and 
hepatic fibrosis
Toll-like receptors (TLRs) are a highly conserved family of receptors 
that recognize pathogen-associated molecular patterns and allow 
the host to detect microbial infection. TLRs are not only important 
in the regulation of innate and adaptive immune responses but are 
also involved in noninfectious inﬂammatory diseases of the cardio-
vascular system, lung, liver, and kidney. Chronic tissue injury leads 
to ﬁbrosis in many organs; transforming growth factor-β (TGF-β) 
and platelet-derived growth factor have been characterized as key 
cytokines that mediate ﬁbrogenesis in several organs, including liver 
and kidney. Seki et al. now report that Toll-like receptor 4 (TLR4) 
is required for hepatic ﬁbrogenesis. Using Tlr4-chimeric mice and 
in vivo lipopolysaccharide (LPS) challenge, they found that hepatic 
stellate cells, the main precursors of myoﬁbroblasts in the liver, are 
the predominant target through which TLR4 ligands promote ﬁbro-
genesis. In quiescent hepatic stellate cells, TLR4 activation upregu-
lated chemokine secretion and induced chemotaxis of Kupﬀer cells. 
In addition, it downregulated the TGF-β pseudoreceptor Bambi, 
thus sensitizing hepatic stellate cells to TGF-β-induced signals and 
inducing unrestricted activation by Kupﬀer cells. In addition, LPS-
induced Bambi downregulation and sensitization to TGF-β were 
mediated by a MyD88/NF-κB-dependent pathway. Indeed, the 
authors showed that Myd88-deﬁcient mice had decreased hepatic 
ﬁbrosis. Thus, modulation of TGF-β signaling by a TLR4–MyD88–
NF-κB axis provides a novel link between proinﬂammatory and 
proﬁbrogenic signals. (Nat Med 2007; 13: 1324–1332)
Juan Oliver
Multipotent stem cells in the adult 
fly kidney
The mammalian kidney has the ability to recover after injury and 
regenerate its function after acute renal failure. While some of the 
new cells are generated by division of fully diﬀerentiated cells, it 
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Reduction of hepatic fibrogenesis in Tlr4-mutant mice. Tlr4-mutant and 
Tlr4-wild-type mice underwent bile duct ligation; collagen deposition 
was evaluated by Sirius red staining.
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in Drosophila may provide important clues for understanding 
mammalian kidney repair and regeneration during injury. (Cell 
Stem Cell 2007; 1: 191–203)
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Diabetic nephropathy in mice 
deficient in decorin
Despite the clinical importance of diabetic renal disease, research 
has been hindered by a lack of murine models with advanced dia-
betic nephropathy. Low doses of streptozotocin fail to produce 
diabetic nephropathy in many strains of experimental type 1 dia-
betic mice. Although reduced renal function and proteinuria have 
been described in mice when streptozotocin is given at high doses, 
it is diﬃcult to separate its potential toxic eﬀect from the eﬀect of 
diabetes alone. Type 2 models, such as the db/db mouse, develop 
early albuminuria and mesangial matrix accumulation, but with-
out further progression of the renal disease. To date, the C57BL/6 
mouse has been considered to be relatively resistant to advanced 
nephropathy and renal failure with diabetes alone. In a recent com-
munication, Williams et al. report that mice deﬁcient in decorin 
(Dcn–/–) develop progressive diabetic nephropathy. Decorin is a 
proteoglycan of unclear function that inhibits active TGF-β and 
that has been found to be increased in diabetic nephropathy. The 
investigators used low-dose streptozotocin to induce type 1 diabe-
tes in wild-type (C57BL/6J Dcn+/+), Dcn–/–, and Dcn+/– mice and 
studied the mice for up to 1 year. They found that the decorin gene 
dose had no eﬀect on the severity of diabetes. However, the Dcn–/– 
diabetic mice died signiﬁcantly earlier than nondiabetic controls, 
and, in contrast to wild-type diabetic mice, which failed to develop 
signiﬁcant nephropathy, Dcn–/– diabetic mice developed a signiﬁ-
cant increase in albuminuria and plasma creatinine, and a con-
current decrease in circulating adiponectin levels. Dcn–/– diabetic 
mice exhibited advanced glomerular lesions (Figure), including 
diﬀuse mesangial matrix accumulation and ﬁbrin cap formation. 
Dcn–/– diabetic mice also exhibited increases in glomerular TGF-β, 
type I collagen, macrophage inﬁltration, and Nox4. These results 
indicate that decorin is a natural protective factor against diabetic 
nephropathy and suggest that the Dcn–/– diabetic mouse may be 
a useful new model of progressive diabetic nephropathy. (Am J 
Pathol 2007; 171: 1441–1450)
Juan Oliver
has been proposed that stem cells and progenitor cells also 
contribute to the repair and regeneration of injured renal tis-
sue. Analysis of renal stem cells in vertebrates has been hin-
dered by the kidney’s morphological complexity. Some of the 
best-understood organ-speciﬁc stem cells are in the ovary and 
testis of Drosophila melanogaster. Although studies on stem 
cells in ﬂies have proven invaluable to better understand the 
reproductive system, no stem cells have been identiﬁed in the 
Malpighian tubules (the ﬂy equivalent of the mammalian kid-
ney) in Drosophila (Figure), which are thought to be very stable. 
Malpighian tubules consist of several cell types, some derived 
from the epithelial tube and some from the neighboring meso-
derm, which integrate into the epithelium upon a mesenchy-
mal-to-epithelial transition. In a recent communication, Singh 
et al. identiﬁed multipotent stem cells in the region of lower 
tubules and ureters of the Malpighian tubules. Using lineage 
tracing and molecular marker labeling methods, they found 
that the stem cells generated all cell types of the adult organ. 
They designated these cells as ‘renal and nephric stem cells’ 
(RNSCs); approximately 100 RNSCs were found in one pair of 
anterior Malpighian tubules. This is a surprisingly high number, 
as an entire pair of anterior Malpighian tubules contains only 
about 500 cells. Thus, a large number of multipotent cells were 
found to be in close proximity to their progeny instead of 
being located in a speciﬁc ‘niche.’ These results suggest that the 
Malpighian tubules are much more dynamic than previously 
believed. Singh et al. also discovered that JAK–STAT signaling 
regulated the stem cells’ self-renewal. Absence of JAK–STAT 
signaling promoted diﬀerentiation of the RNSCs, caused loss 
of the stem-cell population, and increased the size of the Mal-
pighian tubules by accelerating the rate of RNSC division. Since 
RNSCs expressed both the ligand and the receptor, self-renewal 
was controlled by autocrine JAK–STAT signaling. The ﬁnding 
that JAK–STAT signaling is critical in the maintenance of the 
RNSCs is of great interest, because this system plays a similar 
role in several other organs, such as the testis and ovary. Fur-
ther, it has long been known that mouse embryonic stem cells 
will not diﬀerentiate and will only proliferate as long as the 
JAK–STAT pathway is activated by leukemia inhibitory fac-
tor. Needless to say, identiﬁcation of adult kidney stem cells 
(Left) Glomerular fibrin cap lesions, seen only in diabetic Dcn–/– glomeruli 
(arrow). (Right) Electron micrograph of a glomerulus fibrin cap.
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The Drosophila Malpighian tubules and their cells.
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